AstraZeneca: EMA validates Dato-DXd for two cancers
The first decision concerns the treatment of locally advanced or metastatic non-squamous non-small cell cancer requiring systemic therapy after previous treatment.
The other concerns HR-positive, but HER2-negative, non-operable or metastatic breast cancer in patients whose disease has progressed and who cannot benefit from endocrine therapy following initial systemic therapy.
Datopotamab deruxtecan - or Dato-DXd - is an antibody-drug conjugate developed in collaboration with Japan's Daiichi Sankyo.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction